In a report released on March 14, Jessica Fye from J.P. Morgan maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

With another JP Morgan in the rearview mirror ... Andrew Obershain, CEO of bluebird bio, said as much on stage. A year before the FDA approved his company’s gene therapy for sickle cell ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

NeueHealth Inc (NEUE) is expected to report for 4Q. NeuroMetrix Inc (NURO) is expected to report for 4Q. Nikola Corp (NKLAQ) is expected to report for 4Q. Nu Ride Inc (NRDE) is expected to report for ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

EverSource Wealth Advisors LLC raised its position in shares of JPMorgan Chase & Co. (NYSE:JPM – Free Report) by 2.8% in the ...

Hollencrest Capital Management reduced its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM – Free Report) by 0.2% in the ...

Michael Kim, founder of MBK Partners, faces scrutiny amid controversial dealings and increasing legal challenges in Korea.

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

In the same investor note, JP Morgan slashed its price target for Tesla shares to a mere $120, representing more than a 50% ...

JP Morgan analysts said that Tesla could end Q1 with just 355,000 deliveries globally. This would represent an 8% over-year-over decline from the first quarter of 2024. The same analysts also ...